Paris-based Waiv has secured $33M in funding to accelerate its AI-driven precision medicine platform, with the round led by OTB Ventures and Alpha Intelligence Capital. The company, led by CEO Meriem Sefta, focuses on transforming routine digital histopathology and multimodal clinical data into actionable diagnostic insights for oncology. This capital infusion will support the expansion of its clinical-grade test portfolio, including products like RlapsRisk BC and MSIntuit Suite, while deepening integration into pharmaceutical R&D pipelines and broadening international market access.

Waiv operates at the intersection of computational pathology and digital diagnostics, addressing the critical need for rapid, high-accuracy patient stratification in cancer care. By leveraging AI to extract biological insights from standard clinical data, the company competes with established digital pathology firms and diagnostic software providers that struggle to integrate multimodal datasets efficiently. As the global precision medicine market continues to grow at a projected CAGR of over 10 percent, Waiv occupies a vital position in the software-as-a-service value chain by streamlining diagnostic workflows and reducing the time required for biomarker discovery.

This funding signals a shift toward data-native diagnostic tools that prioritize clinical utility and integration within existing hospital infrastructure. Investors are increasingly betting on companies that can prove immediate therapeutic impact through improved testing accuracy rather than just theoretical research. Industry observers should monitor Waiv for upcoming clinical validation results and strategic partnerships with major pharmaceutical entities as they scale their footprint across European and North American markets.